Fluorescent Immortalized Human Adipose Derived Stromal Cells (hASCs-TS/GFP+) for Studying Cell Drug Delivery Mediated by Microvesicles

Author(s): Valentina Cocce, Luigi Balducci, Maria L. Falchetti, Luisa Pascucci, Emilio Ciusani, Anna T. Brini, Francesca Sisto, Giovanna Piovani, Giulio Alessandri, Eugenio Parati, Laura Cabeza, Augusto Pessina*.

Journal Name: Anti-Cancer Agents in Medicinal Chemistry

Volume 17 , Issue 11 , 2017

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: A new tool for the drug delivery is based on the use of Mesenchymal Stromal Cells (MSCs) loaded in vitro with anti-cancer drugs. Unfortunately, the restricted lifespan of MSCs represents a significant limitation to produce them in high amounts and for long time studies. Immortalized MSCs from adipose tissue (hASCs) have been generated as good source of cells with stable features. These cells could improve the development of standardized procedures for both in vitro and preclinical studies. Furthermore they facilitate procedures for preparing large amounts of secretome containing microvesicles (MVs).

Method: We used human adipose tissue derived MSCs immortalized with hTERT+SV40 (TS) genes and transfected with GFP (hASCs-TS/GFP+). This line was investigated for its ability to uptake and release anticancer drugs. Microvesicles associated to paclitaxel (MVs/PTX) were isolated, quantified, and tested on pancreatic cancer cells.

Results: The line hASCs-TS/GFP+ maintained the main mesenchymal characters and was able to uptake and release, in active form, both paclitaxel and gemcitabine. From paclitaxel loaded hASCs-TS/GFP+ cells were isolated microvesicles in sufficient amount to inhibit “in vitro” the proliferation of pancreatic tumor cells.

Conclusion: Our study suggests that human immortalized MSCs could be used for a large scale production of cells for mediated drug delivery. Moreover, the secretion of drug-associated MVs could represent a new way for producing new drug formulation by “biogenesis”. In the context of the “advanced cell therapy procedure”, the MVs/PTX production would use less resource and time and it could possibly contribute to simplification of GMP procedures.

Keywords: Mesenchymal stromal cells, immortalized MSCs, paclitaxel, gemcitabine, microvesicles, drug delivery.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 17
ISSUE: 11
Year: 2017
Page: [1578 - 1585]
Pages: 8
DOI: 10.2174/1871520617666170327113932
Price: $58

Article Metrics

PDF: 19
HTML: 1
EPUB: 1